Mantle Cell Lymphoma
Clinical research in Mantle Cell Lymphoma focuses on adult patients with indolent disease and treatment-naïve presentations, with interest in immunotherapy and BTK inhibitor-based combinations. The sponsor also supports studies in clinically indolent forms where rituximab is paired with targeted agents to address frontline treatment needs.
- Indolent Mantle Cell Lymphoma
- Ibrutinib and rituximab
- Pirtobrutinib and rituximab
These trials reflect a strong therapeutic interest in non-chemotherapy approaches for MCL across multicenter settings.
Diffuse Large B-Cell Lymphoma
Research in Diffuse Large B-Cell Lymphoma includes patients with late relapse and first relapse settings, with emphasis on cellular therapy and bispecific antibody strategies. The sponsor’s portfolio includes evaluation of treatments designed for relapse/refractory large B-cell lymphoma and second-line disease control.
- Late-relapse DLBCL
- Axicabtagene ciloleucel
- Epcoritamab
Active trials in this area are distributed across multiple research sites and countries, supporting access to advanced lymphoma therapies.
Classical Hodgkin Lymphoma
The sponsor is involved in studies for relapsed/refractory classical Hodgkin lymphoma, with attention to salvage treatment options and metabolic response assessment. Research activity centers on combinations that include brentuximab vedotin alongside established chemotherapy backbones in patients who require second-line disease control.
- Relapsed/Refractory cHL
- Brentuximab vedotin
- Salvage therapy
These studies address therapeutic choices for patients with persistent or recurrent Hodgkin lymphoma after prior treatment.
Targeted and Immune-Based Hematologic Therapy
Across its portfolio, the sponsor supports research into targeted therapy, cell therapy, and immune-based combinations for B-cell malignancies. The funded trials explore agents such as ibrutinib, pirtobrutinib, axicabtagene ciloleucel, and epcoritamab in settings where conventional immunochemotherapy is being compared with newer treatment strategies.
- BTK inhibitors
- CAR-T therapy
- Bispecific antibodies
The clinical landscape is concentrated in hematologic oncology, with emphasis on advanced therapies for lymphoma.
